who should not take glp-1 receptor agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways GLP-1 Medications: Who Should Avoid
Description
In this article the second in my series on GLP-1 drugs (see the first one here) I explore the science and clinical journey that brought these agents from niche treatments to global disruptors
20 in the journal Nature Medicine
Public interest in, and use of, GLP-1 and GLP-1/GIP medications for weight loss is growing rapidly
The cagrilintide side effect profile adds some considerations beyond standard GLP-1 effects
1999;276(6 Pt 1):E1049E1054
